Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Polycystic Ovary Syndrome 14Breast Neoplasms 11Prostatic Neoplasms 9Obesity 7Insulin Resistance 6Carcinoma, Non-Small-Cell Lung 5Lung Neoplasms 4Colorectal Neoplasms 4Motor Activity 3Adenocarcinoma of Lung 3Squamous Cell Carcinoma of Head and Neck 2Pancreatic Neoplasms 2Neoplasms 2Menstruation Disturbances 2Lymphoma, Large B-Cell, Diffuse 2Head and Neck Neoplasms 2Endometrial Neoplasms 2Diabetes Mellitus 2Weight Loss 1Urothelial Cancer 1Thyroid Diseases 1Thoracic Neoplasms 1Smoldering Multiple Myeloma 1Rectal Neoplasms 1Prediabetic State 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pleural Effusion, Malignant 1Overweight 1Ovarian, Fallopian Tube, and Primary Peritoneal Cancer 1Non-alcoholic Fatty Liver Disease 1

Interventions

Sunitinib 64Nivolumab 42pembrolizumab 36Bevacizumab 32Everolimus 31Sorafenib 25pazopanib 23Axitinib 23cabozantinib 14aldesleukin 13Ipilimumab 13temsirolimus 11Interferon alpha-2 11Cyclophosphamide 10avelumab 9Magnetic Resonance Spectroscopy 9Interleukin-2 9lenvatinib 8atezolizumab 8Radiosurgery 8Gemcitabine 8Immunoglobulin G 7Erlotinib Hydrochloride 7Disulfides 6fludarabine phosphate 5Radiotherapy 5Fluorodeoxyglucose F18 5peginterferon alfa-2b 4Vorinostat 4Tyrosine Kinase Inhibitors 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Carcinoma, Renal Cell × Metformin × Clear all
NCT02495103 2021-01-26

Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
7 enrolled 10 charts
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡